Corticotropin Patent Expiration
Corticotropin is used for promoting new vessel formation in ophthalmic diseases. It was first introduced by Sanofi Aventis Us Llc
Corticotropin Patents
Given below is the list of patents protecting Corticotropin, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Purified Cortrophin Gel | US11975047 | Methods for storing and warming purified corticotropin compositions | Oct 27, 2043 | Ani Pharms |
| Purified Cortrophin Gel | US12102662 | Methods for storing and warming purified corticotropin compositions | Oct 27, 2043 | Ani Pharms |
| Purified Cortrophin Gel | US12233105 | Methods for storing and warming purified corticotropin compositions | Oct 27, 2043 | Ani Pharms |
| Purified Cortrophin Gel | US12324787 | Contactless optical process for identifying objects | Oct 27, 2043 | Ani Pharms |
| Purified Cortrophin Gel | US12440542 | Oct 27, 2043 | Ani Pharms | |
| Acthar Gel | US11752199 | Methods of modulating pericytes | Jul 18, 2041 | Mallinckrodt Ireland |
| Acthar Gel (autoinjector) | US11752199 | Methods of modulating pericytes | Jul 18, 2041 | Mallinckrodt Ireland |
About Veterinary Corticotropin
Corticotropin is used in a drug marketed by 1 company: Bimeda Animal Health Ltd.
Other drugs containing Corticotropin are: Acth gel .
Corticotropin's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Corticotropin:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Corticotropin for Behçet's Disease: A Multicenter Randomized Controlled TrialAcronym. | Peking University People's Hospital | NA |
NOT YET RECRUITING
(Sep 1, 2026)
| PHASE2 |
| The Effect of Sulfasalazine on CRH Levels in Pregnant Women | Rutgers, The State University of New Jersey | NA |
RECRUITING
(Jul 1, 2026)
| PHASE2 |
| CRF2 Agonist for the Treatment of Worsening Heart Failure | Corteria Pharmaceuticals | NA |
SUSPENDED
(Jul 1, 2026)
| PHASE2 |
| Prospective Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Ectopic Cushing Syndrome | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | NA |
RECRUITING
(May 8, 2026)
| PHASE2 |
| Subjective Experience Following Psilocybin | University of Calgary | NA |
RECRUITING
(May 1, 2026)
| PHASE2 |